NSE: PGHL · BSE: 500126 · ISIN INE199A01012
Procter & Gamble Health Limited stock analysis
Procter & Gamble Health Limited ranks #701 in the TickerSutra evidence-ranked universe with a score of 61/100 and 95% data confidence. The latest captured fundamentals show ROCE of 83.9%, quarterly sales growth of 7.4% and quarterly profit growth of 9.5%.Monitor only
INVESTMENT EVIDENCE
What supports—and challenges—the thesis
Evidence in favour
- ROCE is 83.9%
- Low debt/equity of 0.02×
- CWIP indicates an active capacity pipeline
- No promoter shares are reported as pledged
Risks and constraints
- No calculated threshold risk in the current snapshot.
Still unresolved: Related-party exposure · Broad media sentiment
FINANCIAL TRAJECTORY
Recent operating history
| Period | Revenue | Operating profit | Net profit | Operating margin |
|---|---|---|---|---|
| 2022 | ₹1,114cr | ₹268cr | ₹193cr | 24.0% |
| 2023 | ₹1,230cr | ₹325cr | ₹229cr | 26.0% |
| 2024 | ₹1,151cr | ₹307cr | ₹201cr | 27.0% |
| 2025 | ₹934cr | ₹319cr | ₹234cr | 34.0% |
| 2026 | ₹1,408cr | ₹459cr | ₹327cr | 33.0% |
| TTM | ₹1,433cr | ₹466cr | ₹357cr | 33.0% |
EXCHANGE EVENT TRIGGERS
Latest corporate disclosures
We would like to inform you that the Trading Window of the Company shall remain closed for the Directors and Designated Employees from October 1, 2026 until 48 hours from the publication ....
RoutineProcter & Gamble Health Ltd - 500126 - Intimation Regarding Ease Of Doing Investment - Special Window For Transfer And DematerializationBSE · 19 Sept 2026Stock Exchange is informed about an update on Ease of doing Investment - Special Window for Transfer and Dematerialization.
RoutineUpdatesNSE · 19 Sept 2026Procter & Gamble Health Limited has informed the Exchange regarding 'Update on Intimation Regarding Ease of Doing Investment - Special Window for Transfer and Dematerialization'.
MANAGEMENT COMMENTARY
Signals from filed documents
We also continue to improve in-market execution across all channels and platforms. We remain confident that the best path forward is to double-down on this strategy that has enabled strong results over the last five years, and which is the foundation for balanced growth and value creation. Annual Report 2025-26 10 Procter & Gamble Health LimitedHealth Public health concerns such as Vitamin Deficiencies, Neuropathy, I
The Nomination and Remuneration Policy is in compliance with all applicable provisions of the Companies Act, 2013, particularly Section 178 read together with the applicable rules thereto and Regulation 19 of the SEBI (LODR) Regulations, 2015. The Policy is designed to attract, motivate and retain leadership members in a competitive and international market. The Policy reflects 62 Annual Report 2025-26 Procter & Gamb
SECRETARIAL STANDARDS During the Financial Year, the Company has complied with the mandatory Secretarial Standards issued by the Institute of Company Secretaries of India. MATERIAL ORDERS PASSED BY THE REGULATORS AND COURTS During the Financial Year under review, no regulator or court has passed any significant and/or material orders impacting the going concern status of the Company and its future operations. ACKNOWL
(Yes/No) Yes, the Company has adopted P&G’s Worldwide Business Conduct Manual (WBCM), as its Business Responsibility policy, which sets forth global standards, covering all NGRBC Principles. Has the policy been approved by the Board? The Board of the Company at its meeting held on August 8, 2019, had approved P&G’s WBCM, as Company’s Business Responsibility policy.
He has over 35 years of intrapreneurship in India and international markets in diverse industries including pharmaceuticals, OTC, automotive catalysts and specialty chemicals. He has vast expertise in strategic and operational areas including greenfield setups, upscaling of businesses, risk management and diversification. Milind Thatte Managing Director Mr.
Vice President & General Manager, Consumer Healthcare for the Asia-Pacific, India, Middle-East & Africa region. Analyst Meet One meeting with analysts and institutional investors was held during the Financial Year. Details of the same are hosted on the website of the Company at https:/ /www.pghealthindia.com/ investors/#analyst-investors-meeting.
HOW TO READ THIS PAGE
Evidence, freshness and limitations
What does the TickerSutra score mean?
The score ranks captured evidence across financial quality, growth, moat and margins, regulatory catalysts, governance, institutional trend and valuation comfort. It is a research-prioritization tool—not a buy recommendation or price target.
Which sources support this page?
Financial history, ownership and pledge data, NSE and BSE filings, annual reports and available earnings-call transcripts are combined here. Use the source trail and original exchange document before relying on a decision-critical fact.
Why can an item be unresolved?
Unresolved means the current captured source window did not provide enough evidence for that check. It does not establish that a risk or relationship is absent.
Maintained by TickerSutra Research · Snapshot updated 29 Sept 2026 · Read the methodology · Read the disclaimer
DIRECTOR & BUSINESS NETWORK
Loading corporate intelligence
Loading universe coverage and exchange-backed evidence…